Open Clinical Trials

For a complete list ofclinical trials available in our practice, please view Clinical Trials Newsletter Winter 2007/2008

BREAST

MBC Doxil/Carboplatin

Phase II Study of Doxil and Carboplatin in Metastatic Breast Cancer (MBC).

Std Chemo +/- Bevacizumab for TMBC Ribbon 2

A Phase III, Multicenter, Randomized, Placebo-Controlled Trial Evaluating The Efficacy And Safety of Bevacizumab In Combination With Chemotherapy Regimens In Subjects wtih previously treated Metastatic Breast Cancer.

TAC vs. TC for Adjuvant Breast Cancer

Phase II Trial of Adjuvant TC versus TAC in HER2-Negative Early Stage Breast Cancer Patients.

Gem/Carbo +/- BSI201 Triple Neg MetBrCa

A Phase 2, Multi-center, Open-label, Randomized Trial of Gemcitabine/Carboplatin, with or without BSI-201, in patients with ER, PR, and HER2-negative metastatic breast cancer.

Trastuzumab-DM1 HER2+ MetBrCa

A Phase II, Single-Arm, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients with HER2- Positive Metatstatic Breast Cancer Who Have Progressed while Receiving HER2-Directed Therapy.

Letrozole vs. Placebo in Women w/ 5+ Yrs Aromatase Inhibitor

Phase III Study of Femara vs Placebo in Women who have recived 5 or more years of an Aromatase Inhibitor.

TAILORx Assiging Individual Options for Trt, Node-, ER+, PR+

Trial Assigning Individualized Options for Treatment (Rx) in Node Negative, ER and PR Positive Patients

BLADDER

Rand DC Lapatinib ErbB2+ Ov/GE/Endo/Blad

A Phase II, Placebo-Controlled, Double-Blind, Randomized, Discontinuation Study of Lapatinib Administered Orally to Subjects with ErbB2 Positive Ovarian, Gastric/Esophageal Adenocarcinoma, Uterine Serous Papillary, or Bladder Cancer.

ENDOMETRIAL

Rand DC Lapatinib ErbB2+ Ov/GE/Endo/Blad

A Phase II, Placebo-Controlled, Double-Blind, Randomized, Discontinuation Study of Lapatinib Administered Orally to Subjects with ErbB2 Postivie Ovarian, Gastric/Esophageal Adenocarcinoma, Uterine Serous Papillary, or Bladder Cancer.

ESOPHAGEAL

Rand DC Lapatinib ErbB2+ Ov/GE/Endo/Blad

A Phase II, Placebo-Controlled, Double-Blind, Randomized, Discontinuation Study of Lapatinib Administered Orally to Subjects with ErbB2 Positive Ovarian, Gastric/Esophageal Adenocarcinoma, Uterine Serous Papillary, or Bladder Cancer.

GASTRIC

Rand DC Lapatinib ErbB2+ Ov/GE/Endo/Blad

A Phase II, Placebo-Controlled, Double-Blind, Randomized, Discontinuation Study of Lapatinib Adminstered Orally to Subjects with ErbB2 Positive Ovarian, Gastric/Esophageal Adenocarcinoma, Uterine Serous Papillary, or Bladder Cancer.

LUNG

Human Genome Science

Multi-arm Phase II Trial of Mapatumumab plus Carboplatin and Paclitaxel in first line lung cancer.

Merck START Trial

Study of Vaccine STIMUVAX in Patients with Unresectable Stage II Disease.

MYELOMAS

USO #06108

Randomized Phase 3b Study of Three Treatment Regimens in Subjects wtih Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE  (Bortezomib), Thalidomide, and Dexamethasone (VTD) versus VELCADE and Dexamethasone (VD) versus VELCADE, Melphalan, and Prednisone (VMP).

OVARIAN

Rand DC Lapatinib ErbB2+ Ov/GE/Endo/Blad

A Phase II, Placebo-Controlled, Double-Blind, Randomized, Discontinuation Study of Lapatinib Administered Orally to Subjects with ErbB2 Postive Ovarian, Gastric/Esophageal Adenocarcinoma, Uterine Serous Papillary, or Bladder Cancer.

PROSTATE

Docetaxel/Predisone A+/_AT-101 1stLine HRPC

A Randomized, Double Blind, Placebo Controlled, Multicenter, Phase 2 Study Comparing AT-101 in Combination with Docetaxel and Prednisone versus Docetaxel and Prednisone in Men wtih Chemotherapy Naive Metastatic Hormone Refractory Prostate Cancer (HRPC).